Author: healthadmin

Type 2 diabetes (T2D) and obesity are metabolic diseases with many causes, including overlapping and distinct genetic features. Polygenic risk scores (PRS) capture multiple genetic risk factors and can estimate whether a person is likely to develop a complex medical condition and how they will cope in the long term. Researchers at Massachusetts General Brigham have built a metabolic PRS to predict obesity and T2D by integrating genetic findings from some of the world’s largest biobanks. It outperformed existing disease prediction models and predicted downstream morbidity and clinical interventions. The survey results are posted below cell metabolism. Our aim…

BioMarin is focused on its CNP analog, Voxzogo, to write the next chapter of the company’s growth story, but changes to its clinical development plan are adding further uncertainty to the company’s calculations. BioMarin will discontinue dosing and enrollment in its Phase 2 trial of Voxzogo, currently approved for achondroplasia, a form of dwarfism, in three potential indications: Turner syndrome, SHOX deficiency, and aggrecan (ACAN) deficiency. The move follows reports of “several” slipped femoral epiphysis (SCFE) events, in which the femoral head slips out of place, in two investigator-initiated trials of the drug, BioMarin said in a March 16 securities…

Extending the duration of monitoring for severe pregnancy complications shows that traditional delivery-focused monitoring misses more than 40% of cases, according to a new study published in . CMJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.251425 This extended monitoring from pregnancy to 6 weeks postpartum. Severe maternal morbidity (SMM) refers to complications during pregnancy that can cause death, prolonged hospitalization, or long-term disability. Current practice in Canada is to monitor and report cases of SMM during labor and delivery, but evidence suggests that extending the surveillance period from pregnancy to 6 weeks postpartum may be beneficial and consistent with World Health Organization…

Colorectal cancer remains one of the leading causes of cancer-related death worldwide, primarily due to metastasis and limited response to immunotherapy in most patients. Although immune checkpoint inhibitors have revolutionized the treatment of certain tumor subtypes, the majority of colorectal cancers remain ‘immune cold’, meaning they are unable to elicit effective antitumor immunity. Increasing evidence suggests that tumor-associated macrophages, particularly the M2 subtype, actively promote tumor growth, invasion, and immunosuppression. However, the molecular signals that drive macrophage polarization within colorectal tumors remain poorly understood. Therefore, understanding how tumor cells reshape immune behavior is essential to improve therapeutic outcomes. Based on…

New research published in natural mental health Higher rates of suicidal ideation and self-harm among older adults with autistic traits suggest that the traits themselves are not directly responsible. Rather, this increased risk appears to be driven by accompanying challenges such as depression, trauma, and social isolation. These findings provide evidence that targeted mental health support and promoting social connections may help protect this vulnerable population. If you or someone you know is experiencing suicidal thoughts or a mental health crisis, help is available. Contact the free and confidential Suicide & Crisis Lifeline by calling or texting 988 or live…

The White House’s direct-to-consumer (DTC) platform TrumpRx is steadily expanding its catalog, with the latest GSK and Amgen products joining the collection of medicines offered through the program. Amgen’s Humira biosimilar Amjevita, migraine drug Aimovig, and cholesterol drug Repatha became available through TrumpRx on Monday. Meanwhile, GSK is offering DTC discounts on some of its Ellipta inhalers and its influenza drug Relenza through its platform. Amjevita is available to cash-paying patients for $299 per month, an 80% discount from the physician’s list price of $1,484. According to the website, Aimovig and Repatha are discounted by 62% off their respective list…

With recent advances in drug discovery research, many drug candidate compounds with high therapeutic efficacy have been developed. However, many of these compounds have characteristics that make them difficult to handle, such as low water solubility and large molecular weights. As a result, it is poorly absorbed into the body, making it difficult to obtain sufficient therapeutic effects. Additionally, the drug is distributed into normal tissues, resulting in severe side effects. Fortunately, research is actively underway to develop drug delivery systems (DDS) that effectively solubilize these compounds and efficiently deliver them to cancer tissues. A research group led by Professor…

High-precision mapping tools can pinpoint where schistosomiasis persists down to the household level, potentially transforming efforts to eradicate the disease, which affects 250 million people, a 13-year study has found. Schistosomiasis is a parasitic infection that affects more than 250 million people worldwide. SciDev.Net. “This is evidence that will help us improve our efforts to eradicate infectious diseases,” Carleton said, explaining that the “last push” is often the most difficult because the parasites settle in small pockets. The study was a collaboration between the Colorado School of Public Health and China’s Sichuan Center for Disease Control and Prevention, with support…

It was just nine months ago that Idolsia announced a CEO change, appointing Srishti Gupta, MD, to its executive team starting July 2025. Now, without any explanation, Mr. Gupta has left the Swiss pharmaceutical company and stepped down from its board of directors. On Monday morning, Idorcia said that Gupta and the board had “mutually agreed” that she would resign. Idosia is searching for a new CEO, while Chairman of the Board Jean-Paul Crozel, MD, is responsible for the day-to-day operations of the pharmaceutical company. “It is a great honor to lead Idorsia and work with such a talented and…

Eli Lilly recorded sales of $408 million in the first full year in the U.S. for its eczema treatment Evgris, which was launched in 2025. Now, after positive results in a Phase 3 trial of an IL-13 inhibitor, an Indianapolis drug company is poised to offer the drug to a younger group of patients. The study, which included 363 patients ages 6 months to 18 years with moderate to severe atopic dermatitis, met key secondary endpoints by reducing disease symptoms while providing skin clearance and itch relief at 16 weeks, Lilly reported Monday. Participants received either a placebo or a…